For laboratory research use only.
What is GHRP-2? GHRP-2, also called pralmorelin or KP-102, is a synthetic hexapeptide that activates the ghrelin receptor (GHS-R1a). It is one of the more potent growth hormone–releasing peptides in published animal data and is used as a reference ligand in secretagogue research. Explicit SARMs supplies GHRP-2 5mg for laboratory research use only.
GHRP-2—also published under names such as pralmorelin and KP-102—is a synthetic hexapeptide growth hormone–releasing peptide developed from the GHRP series. It remains one of the stronger GHS-R1a agonists used as a reference tool in secretagogue research.
Identity under several names
Secondary pharmacology summaries describe pralmorelin/GHRP-2 as a potent GH-releasing peptide with a substantial experimental record across administration routes studied in animals and humans in older literature (pralmorelin/GHRP-2 profile; KP-102 characteristics). Synonyms help literature search; the lot label and sequence still control what was used in an experiment.
Potency and selectivity themes
In comparative swine data presented with ipamorelin, GHRP-2 showed higher GH-release potency than GHRP-6 or ipamorelin, with lower maximal GH efficacy than those comparators in the same report, and with ACTH/cortisol increases that ipamorelin lacked (Raun et al., 1998). Those differences are why selectivity is treated as a design variable when assembling a GHS-R1a panel rather than as a marketing slogan.
Place in the wider GH–IGF toolkit
Recent overviews of peptides that modulate the GH–IGF axis keep GHRPs in a lane separate from GHRH analogs and from IGF receptor ligands (GH–IGF peptide landscape review). GHRP-2 belongs with ghrelin-receptor tools. Pairing it experimentally with a GHRH analog is a two-pathway question, not proof that the molecules are similar.
Limits
Human and animal secretagogue papers are model- and chemotype-specific. They should be cited for the endpoints they measured, not generalized into recovery or performance claims for laboratory listings.
Frequently asked questions
What is GHRP-2 used for in research?
GHRP-2 is used as a reference GHS-R1a agonist in laboratory and animal studies of growth hormone–release signaling, receptor pharmacology and comparisons between secretagogue chemotypes.
Is GHRP-2 the same as pralmorelin?
Yes. Pralmorelin and KP-102 are published names for GHRP-2. The sequence and lot label, not the name, should be used to confirm which material was used in an experiment.
How does GHRP-2 compare with GHRP-6?
Both are hexapeptide GHS-R1a agonists. In Raun et al. (1998), GHRP-2 showed higher GH-release potency than GHRP-6 in swine, and both raised ACTH and cortisol where ipamorelin did not. See our GHRP-6 research overview.
Is GHRP-2 a SARM?
No. GHRP-2 is a peptide that acts at the ghrelin receptor. SARMs are small non-steroidal molecules that act at the androgen receptor; see our SARMs collection for those compounds.
Where can researchers buy GHRP-2?
GHRP-2 5mg is listed in our growth hormone secretagogue peptides collection. Lot documentation is on our lab test results page. For research use only; not for human or veterinary use.
Sources
- Pralmorelin: GHRP 2, GPA 748, growth hormone-releasing peptide 2, KP-102 D, KP-102 LN, KP-102D, KP-102LN. (Drugs R D, 2004, PMID 15230633)
- Pharmacological characteristics of KP-102 (GHRP-2), a potent growth hormone-releasing peptide. (Arzneimittelforschung, 2004, PMID 15646370)
- Ipamorelin, the first selective growth hormone secretagogue. (Eur J Endocrinol, 1998, PMID 9849822)